Literature DB >> 29573912

Trends in Periprosthetic Hip Infection and Associated Costs: A Population-Based Study Assessing the Impact of Hospital Factors Using National Data.

Robert L Brochin1, Kevin Phan2, Jashvant Poeran3, Nicole Zubizarreta4, Leesa M Galatz1, Calin S Moucha1.   

Abstract

BACKGROUND: Periprosthetic joint infection (PJI) is an important cost driver in hip arthroplasty revisions, thus necessitating careful trend monitoring. Recent national trend data are lacking; we therefore assessed national PJI burden, trends in prevalence, and hospitalization costs.
METHODS: We extracted data on hip arthroplasty revisions from the National Inpatient Sample (2003-2013; n = 465,209). Trends in PJI prevalence and hospitalization costs were (1) assessed for the full cohort and (2) stratified by hospital teaching status, hospital bed size (≤299, 300-499, and ≥500 beds), and hospital region (Northeast, Midwest, South, and West). The Cochran-Armitage trend test (PJI prevalence) and linear regression (hospitalization costs) determined significance of trends. Trends were adjusted for patient's age, gender, insurance type, race, Deyo-Charlson comorbidities, obesity, length of stay, and hospital characteristics.
RESULTS: Overall, PJI prevalence was 15.0% (n = 70,011); adjusted prevalence increased from 13.1% in 2003 to 16.4% in 2013 (P < .0001), while adjusted median PJI hospitalization costs increased from $28,240 in 2003 to $31,529 in 2013 (P < .0001). Rural hospitals had the lowest PJI burden (12.5%; n = 4,525), while urban and teaching hospitals had the highest PJI burden (16.4%; n = 40,297). The stratified analyses, particularly in large hospitals (>500 beds), showed that PJI prevalence increased from 13.0% (2003) to 17.4% (2013; a 33.8% increase; P < .0001). Similarly, PJI revision hospitalization costs increased from a median of $27,490 (2003) to $31,312 (2013; a 14% increase; P < .0001).
CONCLUSION: The burden of PJI in hip arthroplasty revision is increasing and-while additional research is needed-there appears to be a particular shift of revision burden to larger hospitals with increasing costs.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  costs; epidemiology; hip arthroplasty revision; periprosthetic joint infection; trends

Mesh:

Year:  2018        PMID: 29573912     DOI: 10.1016/j.arth.2018.02.062

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  8 in total

1.  Risk factors for mortality following one-stage septic hip arthroplasty - a case-control study.

Authors:  Sophia-Marlene Busch; Mustafa Citak; Mustafa Akkaya; Felix Prange; Thorsten Gehrke; Philip Linke
Journal:  Int Orthop       Date:  2021-09-30       Impact factor: 3.075

2.  Current and Future Burden of Periprosthetic Joint Infection from National Claim Database.

Authors:  Hong Seok Kim; Jung Wee Park; Sun Young Moon; Young Kyun Lee; Yong Chan Ha; Kyung Hoi Koo
Journal:  J Korean Med Sci       Date:  2020-12-21       Impact factor: 2.153

3.  An epidemiological analysis of revision aetiologies in total hip arthroplasty at a single high-volume centre.

Authors:  Benjamin Kerzner; Kyle N Kunze; Michael B O'Sullivan; Karan Pandher; Brett R Levine
Journal:  Bone Jt Open       Date:  2021-01-03

4.  [Comparison of DRG revenues between fast and slow-track procedures for a two-stage replacement of prostheses for periprosthetic hip infections in the aG-DRG system 2020].

Authors:  Katja Hierl; Markus Rupp; Michael Worlicek; Florian Baumann; Christian Pfeifer; Volker Alt
Journal:  Orthopade       Date:  2021-04-21       Impact factor: 1.087

5.  Transcriptomic analysis of Streptococcus agalactiae periprosthetic joint infection.

Authors:  Hye-Kyung Cho; Thao Masters; Kerryl E Greenwood-Quaintance; Stephen Johnson; Patricio R Jeraldo; Nicholas Chia; Meng Pu; Matthew P Abdel; Robin Patel
Journal:  Microbiologyopen       Date:  2021-11       Impact factor: 3.139

Review 6.  Addressing the Needs of the Rapidly Aging Society through the Development of Multifunctional Bioactive Coatings for Orthopedic Applications.

Authors:  Tinkara Mastnak; Uroš Maver; Matjaž Finšgar
Journal:  Int J Mol Sci       Date:  2022-03-03       Impact factor: 5.923

7.  Adherence to a reliable PJI diagnostic protocol minimizes unsuspected positive cultures rate.

Authors:  Daniel Pérez-Prieto; Pedro Hinarejos; Albert Alier; Lluïsa Sorlí; Santos Martínez; Lluís Puig; Juan C Monllau
Journal:  BMC Musculoskelet Disord       Date:  2021-08-02       Impact factor: 2.362

8.  Microbiology of Periprosthetic Hip and Knee Infections in Surgically Revised Cases from 34 Centers in Mainland China.

Authors:  Hui-Ming Peng; Zong-Ke Zhou; Fei Wang; Shi-Gui Yan; Peng Xu; Xi-Fu Shang; Jia Zheng; Qing-Sheng Zhu; Li Cao; Xi-Sheng Weng
Journal:  Infect Drug Resist       Date:  2021-06-25       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.